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ABSTRACT: Cocaine, a widely abused psychostimulant, inhibits the dopamine transporter (DAT) by trapping the protein in an
outward-open conformation, whereas atypical DAT inhibitors such as benztropine have low abuse liability and prefer less
outward-open conformations. Here, we use a spectrum of computational modeling and simulation approaches to obtain the
underlying molecular mechanism in atomistic detail. Interestingly, our quantum mechanical calculations and molecular dynamics
(MD) simulations suggest that a benztropine derivative JHW007 prefers a diﬀerent stereoisomeric conformation of tropane in
binding to DAT compared to that of a cocaine derivative, CFT. To further investigate the diﬀerent inhibition mechanisms of
DAT, we carried out MD simulations in combination with Markov state modeling analysis of wild-type and Y156F DAT in the
absence of any ligand or the presence of CFT or JHW007. Our results indicate that the Y156F mutation and CFT shift the
conformational equilibrium toward an outward-open conformation, whereas JHW007 prefers an inward-occluded conformation.
Our ﬁndings reveal the mechanistic details of DAT inhibition by JHW007 at the atomistic level, which provide clues for rational
design of atypical inhibitors.
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■ INTRODUCTION
The dopamine transporter (DAT) terminates neurotransmis-
sion of dopamine by reuptake of the neurotransmitter from the
synaptic cleft back to the dopaminergic neurons.1 Dysfunction
of dopaminergic signaling is associated with a number of
diseases including schizophrenia, Parkinson’s disease, bipolar
disorder, depression, and attention deﬁcit hyperactivity
disorder.2−4 In addition, DAT is the primary target for several
abused psychostimulants, including cocaine and amphet-
amines.5−7 Cocaine, a highly addictive drug, competitively
inhibits the function of DAT, which leads to dopamine
accumulation in the synaptic cleft. DAT inhibition is known to
be the driving force for the locomotor stimulant and reinforcing
properties of cocaine in humans.8 It had been hypothesized that
all DAT inhibitors would produce behavioral eﬀects identical to
those of cocaine, i.e., increased rewarding eﬀects, increased
locomotor activity, and high abuse liability.9−11 However, a
large number of studies over the past 10−15 years have shown
that several classes of DAT inhibitors, such as benztropine
(BZT), modaﬁnil, and some of their analogues have reduced
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rewarding eﬀects, and decreased abuse and addiction
liability.12−14 These compounds are termed “atypical inhib-
itors”.13 Moreover, one of the BZT derivatives, JHW007, was
shown to antagonize the behavioral eﬀects of cocaine and, thus,
it is considered as a potential lead for treating psychostimulant
abuse.15,16 However, an atomistic understanding of the
structural basis for diﬀerential eﬀects of JHW007 and other
atypical inhibitors, which would inform future drug design,
remains unclear.
DAT and other members of the neurotransmitter:sodium
symporter (NSS) family accomplish the thermodynamically
unfavorable transport of substrates across the cell membrane by
undergoing conformational transitions that are driven by the
transmembrane Na+ gradient.7 Furthermore, mammalian NSS
proteins are characterized by cotransport of Cl−.7,17 During the
transport cycle, these transitions follow the alternating access
mechanism,18 in which the protein toggles between outward-
facing (including both outward-open and outward-occluded)
and inward-facing (including both inward-open and inward-
occluded) conformations. The equilibrium between these
conformations can be shifted by mutations and/or ligand
binding.19,20 For a bacterial homologue of NSS, leucine
transporter (LeuT), the outward-open, outward-occluded, and
inward-open conformations have been captured by X-ray
crystallography.21,22 Recent crystal structures of Drosophila
melanogaster DAT (which shares more than 50% sequence
identity with human DAT (hDAT), as opposed to ∼20%
between LeuT and hDAT) have been solved in the presence of
various substrate and inhibitors.23,24 With the exception of the
3,4-dichlorophenylamine (DCP)-bound structure in a “parti-
ally” outward-occluded conformation, all of these structures
were crystallized in outward-open conformations.
Based on the crystal structures of LeuT and dDAT,
computational modeling and simulations have shed light on
molecular mechanisms of the ligand binding as well as
conformational dynamics in hDAT.25−32 In particular, previous
molecular modeling based on the LeuT structure in
combination with a mutagenesis study predicted that cocaine
and its high aﬃnity analog 2β-carbomethoxy-3β-(4-
ﬂuorophenyl)tropane (CFT) disrupted an intramolecular
interaction between Tyr156 and Asp79 in the central binding
(S1) site of hDAT.33 Removal of this interaction by Y156F
mutation did not aﬀect the binding aﬃnity of cocaine or CFT
to DAT, whereas binding of the atypical DAT inhibitor,
JHW007 was reduced.33 The recent crystal structures of dDAT
bound to cocaine or CFT, however, show that the hydrogen
bond between Tyr156 and Asp79 is intact and argue that the
destabilization of this interaction is not directly involved in
promoting the binding of cocaine or CFT.24 Interestingly, the
crystal structure of the Y108F mutant in LeuT (equivalent to
Y156F in hDAT) has been found to be in the outward-open
conformation (PDB ID 3TT121).
Identiﬁcation and characterization of the speciﬁc conforma-
tions that are diﬀerentially stabilized by the atypical and typical
inhibitors are crucial in understanding their mechanisms of
actions. Several studies have investigated the relationship
between the conformational changes in DAT and the atypical
eﬀects of BZT and its derivatives.34,35 In particular, the Y335A
DAT mutation, which has been shown to steer DAT toward the
inward-open conformation,36 was found to aﬀect the binding of
atypical inhibitors much less than cocaine-like inhibitor-
s.34,37Another mutagenesis and docking study demonstrated
BZT and JHW007 interacted with Ala479 and Ala480 in
transmembrane segment 10 (TM10), whereas this interaction
was absent for CFT.38 Taken together, previous studies on
typical and atypical DAT inhibitors showed that the ligand-
induced conformational changes in DAT as well as the binding
mode of ligands have profound eﬀects on the behavioral
response produced by inhibitors. However, these studies have
been limited by the absence of high-resolution DAT structures
and the fact that modeling studies have been limited to docking
or relatively short molecular dynamics (MD) simulations.
Hence, the molecular details of the inhibition mechanism by
atypical inhibitors and importantly, the protein’s conforma-
tional changes induced by these inhibitors remain unclear.
Here we carry out more than 36 μs long MD simulations of
six conditions, including WT and Y156F hDAT in the absence
of any ligand (apo), or the presence of either JHW007 or CFT
(Table 1), which are guided and analyzed with Markov state
models (MSM). MSMs provide an eﬃcient approach by
stitching together a set of relatively short MD simulations into a
single statistical model to describe the dynamics of proteins in
terms of transitions between conformational states,39,40 and
have been successfully applied in revealing protein−ligand
binding modes and protein conformational transitions.41−45
Moreover, a recent MD simulation study in combination with
MSM analysis identiﬁed the role of N-terminus in the
mechanisms of Na+ release from hDAT as the transporter
transitions from outward-facing to inward-facing conforma-
tional states.46 Our results demonstrate that JHW007 stabilizes
hDAT in a conformation in between outward-occluded and
inward-open conformations, whereas CFT and the Y156F
mutation shift the conformational equilibrium toward an
outward-open conformation.
■ RESULTS
Overview of MD Simulations. We ﬁrst carried out
comparative simulations to identify the preferred isomer of
JHW007, in terms of the axial versus equatorial form of the
hydrogen attached to the nitrogen in the tropane ring (tNH),
in binding to hDAT. We then initiated a set of simulations for
six conditions, WT and Y156F hDAT in the absence of any
ligand (apo), or the presence of either JHW007 or CFT, which
are listed in Table 1. To adequately sample diﬀerent hDAT
conformational states and ligand binding modes, the initial
Table 1. Simulated Conditions and Simulation Lengths
construct ligand
no. of
trajectories trajectory lengths (μs)
aggregated
lengths
(μs)
WT apo 12 9 × 0.3, 1 × 0.6,
2 × 0.9
5.10
JHW007
(equatorial)
13 4 × 0.3, 1 × 0.42,
1 × 0.6, 4 × 0.9,
1 × 1.2, 1 × 1.2,a
1 × 0.72a
8.94
JHW007
(axial)
6 2 × 0.6, 2 × 1.5,
2 × 0.9a
6.00
CFT 3 1 × 0.6, 1 × 0.72,
1 × 1.2
2.52
Y156F apo 9 6 × 0.3, 3 × 0.9 4.50
JHW007 11 5 × 0.3, 1 × 0.6,
4 × 0.9, 1 × 1.2
6.90
CFT 3 1 × 0.6, 2 × 0.9 2.40
total 57 36.36
aSimulations performed with the OPLS3 force ﬁeld.
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simulations were followed by several rounds of additional
simulations, in which we restarted trajectories from the under-
sampled microstates according to the MSM analysis (see
Methods). Overall, 57 full-atomistic MD simulation trajectories
with aggregated simulation time of 36.36 μs (Table 1) were
collected.
The Axial and Equatorial Isomers of JHW007 Diﬀer in
Their Stability and Binding to hDAT. Both CFT and
JHW007 are tropane alkaloid derivatives and the tNH can
adopt either an axial or an equatorial conformation (Figure
1A). Solution NMR studies have shown that the aryl
substituents at position 3 of the tropane ring change the
equilibrium between axial and equatorial tNH isomers, which in
turn modulates their activity and selectivity for one monoamine
transporter over another.47 Interestingly, the cocaine and CFT
bound crystal structures of dDAT (PDB IDs: 4XP4 and 4XPG,
respectively) are both in an axial tNH conformation. Compared
to cocaine and CFT, JHW007 lacks a carbonyl oxygen on the
tropane ring that may interact with tNH.
We ﬁrst docked axial and equatorial tNH JHW007 in the S1
site of our hDAT model (see Methods). The S1 site in DAT
can be divided into subsites A, B, and C, as deﬁned by Sørensen
et al.48 Interestingly, both axial and equatorial tNH JHW007
adopted similar binding modes−the positively charged amine
forms a salt bridge interaction with Asp79 in subsite A, and the
ﬂuorophenyl rings are oriented in subsites B and C, but with
diﬀerent rotamers of the methoxy linker for the axial and
equatorial forms. In comparison, in the crystal structures of
dDAT bound with cocaine and CFT, the tropane moiety and a
(ﬂuoro)phenyl ring of these compounds occupy subsites A and
B similarly to JHW007, but they do not protrude to subsite C
as they lack the additional phenyl ring in JHW007.24
In our MD simulations of hDAT, the axial tNH JHW007
isomer was not stable in the S1 site and the interaction with
Asp79 consistently broke, whereas the equatorial tNH of
JHW007 consistently retained its interaction with Asp79
(Figure 1B). Such a drastic diﬀerence between the axial and
equatorial tNH JHW007 isoforms is independent of the force
ﬁeld used, either the CHARMM36/GAAMP or the OPLS3
force ﬁeld (see Methods and Table 1). Based on these MD
simulations, we then carried out MM/GBSA calculations (see
Methods) to estimate the ligand-binding aﬃnities. Our results
indicate that the equatorial tNH JHW007 is the preferred
isomer in the S1 site with either of the force ﬁelds: for the
frames from the simulations with the CHARMM36/GAAMP
force ﬁeld, the MM/GBSA binding energy for equatorial tNH
JHW007 (−57.3 ± 2.7 kcal/mol) is 8.8 kcal/mol lower than
that of axial tNH JHW007 (−48.4 ± 2.3 kcal/mol) (Figure
1C); for the frames from the simulations with the OPLS3 force
ﬁeld, those values are −78.6 ± 5.0 kcal/mol for the equatorial
tNH JHW007 and −71.7 ± 6.0 kcal/mol for the axial tNH
JHW007.
We then carried out quantum mechanical calculations of
standalone CFT molecule in water and found that the energy
diﬀerence between axial and equatorial tNH isoforms is 8.7
kcal/mol; in contrast, that for JHW007 is only 0.9 kcal/mol
(Table 2). The results suggest that the axial isoform of CFT is
signiﬁcantly more dominant than its equatorial form, as the
former is stabilized by an intramolecular hydrogen bond
between tNH and the carbonyl oxygen on the 2-position of the
tropane ring. In the absence of such an interaction in JHW007,
the small energy diﬀerence between the two isoforms allows
speciﬁc external interactions to easily switch the preference to
the equatorial isoform, which is indeed what we observed in the
binding site of hDAT in our MD simulations.
Thus, equatorial tNH JHW007 is the preferred isoform in
binding to hDAT, and therefore we use this form for the
following simulation and analysis, and refer to the complex as
hDAT/JHW007.
MSM Analysis Identiﬁed Distinct Conformational
States. Our MSM analysis of the conformational transitions
and preferences in each of the six simulated conditions was
based on a microstate discretization of the combined simulation
set of all six conditions. In each MSM, these microstates were
further lumped into metastable states (MSs) resulting in one
Figure 1. Equatorial tNH JHW007 is the more stable isoform in the
hDAT S1 site. (A) Structures of CFT (top row) and JHW007 (bottom
row). The axial tNH (left column) and equatorial tNH (right column)
stereoisomers are shown. (B) Distance between the nitrogen of the
tropane ring in JHW007 and the closest oxygen of the carbonyl group
of Asp79 measured throughout all simulations for the axial (cyan) and
equatorial (blue) tNH isoforms of JHW007 bound in WT hDAT.
Results from the OPLS3 force ﬁeld simulations are in dotted lines. (C)
MM/GBSA binding energies of axial (cyan) and equatorial (blue)
tNH JHW007 isomers bound in WT hDAT. Averages and standard
deviations are shown for 500 Bayesian Markov model samples with
100 frames for each MS (of those that have >75% probability to
belong to their respective MSs) derived from the simulations using
CHARMM36/GAAMP force ﬁeld.
Table 2. Quantum Mechanical Potential Energies of Axial
and Equatorial tNH Isoforms of CFT and JHW007a
axial tNH
(hartrees)
equatorial
tNH
(hartrees)
axial−
equatorial
(hartrees)
axial−
equatorial
(kcal/mol)
JHW007 −1262.1768 −1262.1753 −0.0015 −0.9
CFT −927.2953 −927.2814 −0.0139 −8.7
aThe calculations were performed using the DFT method with the
(B3LYP) 6-31G** basis set in a water solvent.
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(for CFT-bound conditions), two (apo conditions), and three
(JHW007-bound conditions) MSs (Figure 2A). Detailed
methods of MD simulation setups and MSM analysis are
described in the Methods.
In order to characterize the MSs, we quantiﬁed the extent of
opening of the extracellular vestibule (EV) of hDAT by
calculating the distance between the extracellular portions of
TM6 and TM10 (DTM6e‑10e) (see Methods and below) as well
as the volume of the EV, which was represented by the number
of water molecules in the EV.49,50 The MSs colored in orange
in Figure 2, which are present in all conditions, have
signiﬁcantly larger DTM6e‑10e and EV volume than the green
and blue MSs (Figures 2), and are more outward-facing. As
references, the DTM6e‑10es are also calculated for the crystal
structures of dDAT bound with CFT and DCP, which are in an
outward-open and a “partially” occluded conformations,
respectively24 (Figure 2B). Because the diﬀerence in DTM6e‑10e
between the orange and green MSs (on average 2.8 Å for all
simulated conditions) is larger than that between the dDAT/
CFT and dDAT/DCP structures (2.2 Å), while the DTM6e‑10e of
orange MSs are similar to that of the dDAT/CFT structure, we
designate the orange MSs as an outward-open conformation,
the green MSs as an outward-occluded conformation, and blue
MSs as an inward-occluded conformation (see below).
Y156F Mutation Shifts the hDAT Conformational
Equilibrium to an Outward-Open Conformation. As the
Y108F mutation in LeuT stabilizes an outward-open con-
formation,21 we hypothesized that the aligned Y156F mutation
in hDAT would promote an outward-open conformation as
well. Indeed, our MSM analysis results indicate that the
equilibrium probability of the outward-open conformation in
the Y156F apo condition (21%) is signiﬁcantly larger than that
in the WT apo condition (10%) (Figure 2A). Thus, the Y156F
mutation has a tendency to shift the transporter toward an
outward-open conformation, which is also demonstrated by its
enlarged EV compared to that of WT (Figure 2B).
Furthermore, we observed that in 4 out of 9 Y156F/apo
trajectories but none of WT/apo trajectories the Na+
dissociates from the Na1 site, a trend that is consistent with
our previous results of LeuT simulations, in which the absence
Figure 2. JHW007, CFT and the Y156F mutation shift hDAT to distinct conformational states. (A) Our MSM analysis identiﬁed three metastable
states (MSs) that correspond to three conformations (outward-open (orange), outward-occluded (green), and inward-occluded (blue)). The area of
each disk representing an MS is proportional to the equilibrium probability (π) in each simulated condition. The values from the maximum
likelihood Bayesian Markov model and the upper and lower 1σ conﬁdence intervals (in upper and lower cases, respectively) for π and transition rates
from 500 Bayesian Markov model samples are shown. (B) Distances between the extracellular portions of TM6 and TM10 (DTM6e‑10e) are plotted
against EV volumes (number of waters in EV) for each MS of each simulated condition. WT and Y156F mutant are represented by squares and
triangles, whereas the apo, JHW007-bound and CFT-bound conditions are indicated by open, solid gray, and hatched ﬁll styles, respectively. As
references, the DTM6e‑10es are also shown for the crystal structures of dDAT bound with CFT (PDB ID: 4XPG) and 3,4-dichlorophenylamine (DCP)
(PDB IDs: 4XPA, 4XPH, 4XPT), which are in outward-open (gray dotted line) and “partially” occluded (pink dotted lines) conformations,
respectively.24 (C) Scatter plot of the distance between centers of mass (COM) of the aromatic rings of Tyr156 and Phe326, and the Phe326 χ1
dihedral angle in each MS of the WT/JHW007 condition. (D) The downward movement of JHW007 in the S1 site is coordinated with the inward
movement of TM6e from outward-open to outward-occluded and to inward-occluded conformation in the WT/JHW007 condition. Averages and
standard deviations are shown for 500 Bayesian Markov model samples with 100 frames for each MS (of those that have >75% probability to belong
to their respective MSs), in panels (B) and (C).
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of Na1 is associated with a more outward-open conformation.51
Together, these results demonstrate that disruption of the
hydrogen bond between Tyr156 and Asp79 by the Y156F
mutation in the apo conditions shifts hDAT toward an
outward-open conformation.
JHW007 Shifts DAT Equilibrium toward an Inward-
Occluded Conformation, whereas CFT Stabilizes the
Outward-Open Conformation. As predicted from previous
structure−function studies of hDAT34,38 and the dDAT/CFT
structure,24 the outward-open conformation prevailed in our
simulations of both the WT/CFT and Y156F/CFT conditions
(Figure 2A). JHW007, on the other hand, induces hDAT to
shift toward the blue MS, which is unique to the JHW007
bound conditions. As the DTM6e‑10e of blue MSs is ∼1.1 Å
shorter than that of the green MSs (Figure 2B), the blue MS
likely represents an intermediate between the outward-
occluded and inward-open conformations and we designate it
as an inward-occluded conformation. Note this designation
alone would be arbitrary because no dDAT structure has been
solved in this conformation, however, based on our analysis
(see below), it is a distinct and more inward-facing
conformation compared to the outward-occluded conformation
(green MS).
Based on our MSM analysis, this inward-occluded con-
formation has the highest equilibrium probability (47%) in the
WT/JHW007 condition (Figure 2A). In Y156F/JHW007, the
inward-occluded conformation is relatively less prevalent (18%)
indicating that the Y156F mutation hampers the transporter
from transitioning toward an inward-occluded conformation, in
the presence of JHW007.
In WT/JHW007, from the outward-open to the outward-
occluded and further to the inward-occluded conformation,
there are coordinated changes between the diphenyl moiety of
JHW007 and the phenyl ring of Phe326. The χ1 rotamer
changes of Phe326 are associated with an increased distance
between Tyr156 and Phe326 (Figure 2C), which results in
signiﬁcant changes of the shape of the S1 site to accommodate
the deeper binding pose of JHW007 (Figure 2D). The eventual
rotation of Phe326 away from the S1 site is accompanied by a
reconﬁguration of the loop (TM6m) between TM6e and
TM6i, and is coordinated with the inward-movement of TM6e
(Figure 2D), which is the hallmark of the observed conforma-
tional transitions in our simulations. The aligned residues of
Phe326, Phe259 in LeuT and Phe325 in dDAT, have been
found to play an important role in both substrate and inhibitor
binding.23,52,53 Recently, a computational allosteric communi-
cation analysis identiﬁed that Phe259 was important for
allosteric coupling between the S1 site and the intracellular
gate region.54 Our results are in line with these ﬁndings and
highlight the importance of Phe326 in hDAT in transducing the
impact of JHW007 to induce the overall conformational
changes of hDAT.
We further quantiﬁed diﬀerences of a few structural features
between the dominant conformations in the WT/JHW007 and
WT/CFT conditions using the pairwise interaction analyzer for
DAT (PIA-DAT) at both residue and subsegment levels (see
Methods). Our analysis identiﬁed that the distances between
extracellular subsegments of WT/CFT are generally larger
(upper-left box in Figure 3B), i.e., more outward-facing,
compared to the WT/JHW007 condition, with the most
prominent change being the rearrangement of TM6e. We used
DTM6e‑10e to characterize diﬀerent MSs (Figure 2B, see above).
On the intracellular side, the increase in distances of the
intracellular subsegments in WT/JHW007 compared to WT/
Figure 3. WT/JHW007 is less outward-facing and more inward-facing than WT/CFT. (A) The transmembrane helices in DAT are divided into
extracellular (“e”), middle (“m”, dark gray), and intracellular (“i”) subsegments (see Methods). (B) The diﬀerences in the distances among TM
subsegments highlight the less outward-facing and more inward-facing features of WT/JHW007 condition compared to WT/CFT. The diﬀerences
of extracellular and intracellular subsegments are boxed in the upper left and lower right regions, respectively. For ligand binding residues, the
distances between their Cα atoms (C) and the χ1 dihedral angles of these residues (D) are compared. The results identiﬁed signiﬁcant changes near
Na1 and Na2 sites, i.e., the dark orange pixels near residues 81 and 321 in (C) for the Na1 site and the dark orange pixel for residue 422 in (D) for
the Na2 site (see text). In these analyses by PIA-DAT, the dominant MSs of the WT/JHW007 and the WT/CFT conditions are used (see
Methods). For (B)−(D), the color is scaled (see the color ramp for each panel) from blue to orange corresponding to higher and lower metric
values, respectively, in the WT/JHW007 compared to the WT/CFT condition.
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CFT (lower-right box in Figure 3B) is consistent with WT/
JHW007 being more inward-facing. The movement of TM5i
toward lipids in WT/JHW007 is the most prominent change
and contributes to the opening of the intracellular gate, as
observed in our previous simulations with bacterial NSS
homologues55,56 (also see Discussion and Conclusions). In
addition, PIA-DAT analysis revealed that the Cα-Cα distance
between Ala81 and Ser321 (Ser321 is an Na1 coordinating
residue) is larger in the WT/CFT condition (Figure 3C),
which is likely correlated with Na1 having a tendency to
dissociate from the Na1 site in this condition. Our PIA-DAT
results also indicate a larger distance between Ile148 in TM3
and Ser429 in TM8, and the rotation of Ser429 side chain in
the WT/JHW007 reﬂecting the accommodation of the
diphenyl moiety of JHW007 (Figure 3C,D).
The transition from the outward-open to the inward-
occluded conformation (Movie S1) would be expected to be
accompanied by volume changes of the EV and the intracellular
vestibule (IV). Indeed, from the analysis of the water counts in
the WT/JHW007 condition, binding of JHW007 leads to
closure of the EV and opening of the IV (Figure 4A,B), which
eventually leads to water penetration from the IV to hydrate the
JHW007 in the S1 site. In addition, the transition from an
outward-facing to inward-occluded conformation is frequently
accompanied by the dislocation of Na2 from its binding site
(Figure 4C), which is accompanied by a change in the χ1
rotamer of Na2 coordinating Ser422 from gauche− to gauche+
(Figure 3D).
Interestingly, the weak binding of the axial tNH JHW007
isomer in the S1 site was not able to induce the transporter to
transition into an inward-occluded conformation (Figure S1).
Taken together, the stable equatorial tNH isoform of JHW007
stabilizes a distinct hDAT conformation that lies between
outward-occluded and inward-open conformations, which is
Figure 4. JHW007 and CFT stabilized hDAT in inward-occluded and outward-open conformations, respectively. Diﬀerent trends of water
penetrations in the extracellular (A), the intracellular (B) vestibules (EV and IV), and the z coordinate of Na2 (C) in the dominant MSs of the WT/
JHW007 (blue) and the WT/CFT (orange) conditions indicate that JHW007 and CFT stabilize inward-occluded and outward-open hDAT
conformations, respectively. Averages and standard deviations are shown for 500 Bayesian Markov model samples with 100 frames for each MS (of
those that have >75% probability to belong to their respective MSs). Inward-occluded (D) and outward-open (E) hDAT conformations are shown
in cylinder representations with water molecules in the EV and IV in red spheres, the ligands in blue (JHW007) and orange (CFT) spheres, Phe326
in sticks, and Na2 in yellow spheres. TM6 and 10 are highlighted with the colors corresponding to the MS in each panel.
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consistent with previous experimental results that JHW007 and
other atypical inhibitors stabilize hDAT conformations that are
more inward-facing than those stabilized by cocaine and its
derivatives.34,57
■ DISCUSSION AND CONCLUSIONS
Many DAT inhibitors showing cocaine-like pharmacological
and in vivo properties, such as cocaine, CFT, and RTI-55 (2b-
carbomethoxy-3b-(4-iodophenyl)tropane),58 all possess a hy-
drogen bond acceptor in the tropane ring that can stabilize their
axial tNH conformation.47 Interestingly, a BZT derivative,
MFZ6-96,59 which has a low Ki(Y156F)/Ki(WT) ratio, also has
a carboxyl group in the tropane ring that stabilizes the axial
tNH conformation. In contrast, the BZT derivatives with higher
Ki(Y156F)/Ki(WT) ratio and atypical in vivo properties, such
as JHW007 and GA 1-6960 do not possess any axial tNH
stabilizing group. Thus, our ﬁnding that JHW007 prefers the
equatorial but not axial tNH isomer in the binding site of
hDAT, and that this isomer stabilizes the transporter in an
inward-occluded conformation, suggest speciﬁc ligand struc-
ture−function features that may diﬀerentiate atypical hDAT
inhibitors.
By carrying out more than 36 μs of MD simulations in
combination with MSM analysis, we sought to identify the
preferred conformation of the hDAT WT and Y156F mutant in
the absence of any ligand, or in the presence of either an
atypical hDAT inhibitor (JHW007), or a cocaine derivative
(CFT) in the S1 site. By integrating MSM analysis into our MD
simulation procedure to restart trajectories based on under-
sampled microstates, we obtained convergence (Figures S2−
S4) in delineating the energy landscape and kinetics of relevant
conformational transitions, which we would have probably not
been able to sample by simply performing 36 μs of
conventional MD.
The comparisons between the hDAT WT/apo and Y156F/
apo simulated conditions, and between WT/JHW007 and
Y156F/JHW007, indicate that Y156F mutation in the S1 site
shifts the transporter toward the outward-open conformation.
By comparing WT/apo, WT/CFT, and Y156F/apo, we found
that the binding of CFT shows an even stronger trend than
Y156F mutation in stabilizing the transporter in the outward-
open conformation. Thus, our results argue that the Tyr156-
Asp79 interaction per se does not have a strong correlation
with the conformations of the transporter, as it is present in the
CFT stabilized outward-open conformation in the WT/CFT
condition, whereas the Y156F/apo and Y156F/JHW007
conditions in its absence have large tendencies to be in the
outward-open conformation than WT/apo and Y156F/
JHW007, respectively. Rather, we propose that the phenotype
of Y156F mutation in shifting the conformational equilibrium
toward outward-open conformation is associated with the
reduced mobility of its aromatic side chain in the S1 site. We
found the χ1 rotamer of Tyr156 or Phe156 can only be in trans
in the presence of a bound ligand (either CFT or JHW007),
whereas in both WT/apo and Y156F/apo conditions, the χ1
rotamer of Tyr156 or Phe156 can also be in gauche−; however,
overall this rotamer populates 60.5% in gauche− in WT/apo, but
37.9% in Y156F/apo; in the orange states (outward-open
conformation) of WT/apo and Y156F/apo, this diﬀerential
trend is even more obvious, 58.9% in WT/apo and only 14.0%
in Y156F/apo.
By comparing WT/apo and WT/JHW007, we found that
JHW007 shifts the equilibrium in an opposite direction to the
inward-occluded conformation. This novel inward-occluded
conformation induced by JHW007 lies between outward-
occluded and inward-open conformations. The higher equili-
brium probability of this conformational state in the WT/
JHW007 condition compared to Y156F/JHW007 condition
suggests two competing driving forces in determining the
conformational equilibrium in Y156F/JHW007: JHW007 shifts
hDAT toward an inward-occluded conformation, whereas the
Y156F mutation shifts it toward the outward-open conforma-
tion. This is consistent with previous mutagenesis studies
showing that the binding aﬃnity for JHW007 to the Y156F
mutant is reduced compared to WT, whereas that for CFT is
not aﬀected (Table 3).33,61
In addition, JHW007 has been found to reduce accessibilities
of the cysteines engineered at the Thr316 of TM662 in the EV
compared to those in the presence of CFT, suggesting that
JHW007 stabilizes a more occluded hDAT conformation.
Interestingly, in the conformations revealed by our MD
simulations and MSM analysis, Thr316 has smaller solvent
accessible surface area (SASA) in the WT/JHW007 condition
than in the WT/CFT condition (Figure S5), which is
consistent with the experimental ﬁndings62 and further validates
the mechanistic relevance of the identiﬁed conformations in
characterizing the molecular actions of these compounds on
hDAT.
In the inward-occluded conformation, the hDAT binding site
is at least partially occluded to the extracellular milieu. Thus, it
is unlikely for JHW007 to bind directly to this conformation.
Based on our results, we propose the recognition mechanism to
be a combination of induced ﬁt and conformational selection:
JHW007 ﬁrst binds to the green metastable state (the dominant
state in the WT/apo condition), then it induces conformational
transition to the blue, inward-occluded, state. From our results,
we conclude that Y156F disrupts the conformational
equilibrium but not the recognition mechanism.
The functions of hDAT are closely regulated by a variety of
elements, and a growing number of DAT interaction proteins
have been detected.14,63−67 These interaction partners have
been shown to alter DAT surface levels and modulate DAT
speciﬁc functions, for which the speciﬁcally associated
conformations of hDAT are yet to be revealed. We hypothesize
that the functional impact of atypical hDAT inhibitors must go
beyond the transporter protein per se by triggering diﬀerent
downstream cellular eﬀects from those initiated by cocaine
binding. Interestingly, a recent study by Zhang et al. shows that
conformational changes in the serotonin transporter (SERT), a
homologue of DAT, directly aﬀect protein kinase G mediated
Table 3. Binding Aﬃnities at the WT and Y156F hDATa
compd DAT WT Ki (nM) n DAT Y156F Ki (nM) n Y156F:WT aﬃnity ratio
CFT (Kd) 13.5 [12.2; 14.9] 21 25 [20; 31] 13 1.9
cocaine 223 [160; 309] 3 321 [235; 438] 3 1.4
JHW007 47 [33; 66] 3 260 [229; 296] 3 5.5
aData taken from refs 33 and 61.
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phosphorylation of the transporter.68 Speciﬁcally, it was
demonstrated that the inward-open conformation of SERT
provides accessibility for Thr276 in the intracellular portion of
TM5 (TM5i) to be phosphorylated by a kinase. An
examination of our hDAT simulations shows that whereas in
the CFT-bound outward-open conformation TM5i is in a
structured helical conformation, in the JHW007-bound inward-
occluded conformation TM5i is partially unwound. Con-
sequently, the residue that aligns to Thr276 of SERT,
Thr261, is exposed to water environment in the JHW007-
bound inward-occluded conformation, resulting in a higher
SASA (Figure S5). In addition, as demonstrated by our PIA-
DAT analysis (Figure 3B), the inward-facing conformation
induced by binding of JHW007 propagated to the TM12i-CT
region, the conformational changes of which have been
associated with the interaction between hDAT and calmodulin
kinase II.67
Taken together, our ﬁndings on potentially common features
of the atypical inhibitors and the atomistic details in their
interactions with hDAT shed lights on the molecular
mechanisms of these inhibitors, which may eventually lead to
design of eﬀective medications to treat cocaine dependence.
■ METHODS
MD Simulations. The hDAT model used as the starting point for
our MD simulations was constructed by homology modeling based on
the dDAT/nortriptyline crystal structure (PDB ID 4M4823) using
MODELER.69 Two Na+ and one Cl− ions resolved in the crystal
structure were also included in the model. The JHW007 and CFT
were docked into the central binding site of the hDAT model using
the induced-ﬁt docking (IFD) protocol70 implemented in the
Schrödinger suite (release 2015-4). The MD simulation systems
were prepared using VMD.71 The all-atom simulations were carried
out with our previously established protocols for NSS molecular
systems.50,72 Brieﬂy, hDAT was placed into explicit 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine lipid bilayer (POPC) using the
orientation of dDAT/nortriptyline structure (PDB ID 4M48) from the
Orientation of Proteins in Membranes database.73 Na+ and Cl− ions
corresponding to 0.15 M concentration were added. The simulations
were carried out using NAMD74 with the CHARMM36 force ﬁeld.75,76
The ligand parameters were obtained through the GAAMP server77
with the initial force ﬁeld based on CHARMM general force ﬁeld
(CGenFF) assigned by ParamChem.78 Simulations were performed
with a cutoﬀ of 12 Å for the nonbonded interactions, and the particle
mesh Ewald method was used to evaluate long-range electrostatic
eﬀects. In the isothermal−isobaric (NPT) ensemble, constant
temperature (310 K) was maintained with Langevin dynamics, and 1
atm constant pressure was achieved with the hybrid Nose-Hoover
Langevin piston method79 on an anisotropic ﬂexible periodic cell, with
a constant-ratio constraint applied on the lipid bilayer in the X−Y
plane. The systems were initially minimized for 6000 steps, then a time
step of 1 fs was used for the ﬁrst 200 ps, which was then increased to 2
fs for the rest of the simulations.
To demonstrate that the binding mode diﬀerences between axial
and equatorial isoforms of JHW007 are force ﬁeld independent, we
carried out additional simulations using Desmond MD systems (D. E.
Shaw Research, New York, NY) and OPLS3 force ﬁeld80 with the
same simulation protocol described above.
MSM Analysis. The MSM analysis40,81−84 was performed using the
pyEMMA program (version 2.0.485,86) as described previously.41,87 In
order to describe the conformational changes in hDAT upon the
mutation and binding of ligands, interhelical distances of the
extracellular portions of the core-TMs of “LeuT-fold” transporters,
i.e. TMs 1, 3, 6, 8, and 10 were chosen for the input featurizer. These
distances were calculated using centers of mass (COMs) of Cα atoms
of the following residues: 89−92 (TM1), 169−172 (TM3), 308−311
(TM6), 405−408 (TM8), and 470−473 (TM10). Thus, a total of 10
distances were used as input coordinates.
For the combined data set of all simulated conditions, the slow
linear subspace of the input coordinates was estimated by a time-
lagged independent component analysis (TICA),88,89 and its
dimensionality was reduced by projecting on the three slowest
TICA components (which represent 71% of the cumulative kinetic
variance90). We then performed k-means clustering to discretize this
simulated subspace into 100 cluster centers (microstates). For a range
of numbers of microstates (50, 100, 200, 1000), we had estimated an
MSM for each situation, and concluded that the 100-state MSM
performs best based on two criteria. First, the 100-state MSM has the
highest score in terms of the variational principle,91,92 using cross-
validation93 (Table S1), which we adapted from the MSMBuilder
package94 (in the adaptation, in order to use kinetic variance90 as a
variational score, we changed Σi = 1m λi to Σi = 1m λi2 for the training score,
where λi is the ith slowest eigenvalue and m is the number of
eigenvalues). Second, the 100-state MSM shows better convergence of
the implied time scales in terms of the lag time (Figures S2 and S6−
S8).
We then divided this discretized combined data set by individual
simulated conditions, from each of which we estimated a Bayesian
Markov model.95 Implied relaxation time scales (ITSs)96 for the
transitions between these clusters were obtained as a function of
various lag times (Figure S2). The Bayesian sampling was employed to
compute statistical uncertainties of 500 transition matrix samples at
each lag time. Convergences of ITSs for all MSMs was achieved at a
lag time of 120 ns, which we thus consistently use for all our analyses.
The PCCA++ method97 was then used on each model to lump the
resulting microstates into MSs. The structural and kinetic analysis was
performed on those microstates that have more than 75% of
probability to belong to a particular MS. The transition rates shown
in Figure 2A are inverse mean ﬁrst passage times, which were
computed as previously described,98 and π represents the stationary
equilibrium probability of a given MS.
The MSMs were validated using Chapman-Kolmogorov tests
(Figure S3 and S4),40 which showed that the MSMs estimated at
120 ns were consistent with the simulation data within the 95%
conﬁdence interval computed by 500 bootstrapped samples of
trajectories.99 Generally, the Chapman−Kolmogorov test checks if
the MSM models estimated at lag time τ can be used to make
predictions for the data at longer times kτ within statistical error, i.e., if
eq 1 can be satisﬁed:
τ τ=P k P( ) ( )k (1)
where P(τ) is the transition matrix estimated from the data at lag time
τ (the Markov model), and P(kτ) is the transition matrix estimated
from the same data at longer lag times kτ. In practice, we use P(kτ)
and Pk(τ), respectively, to propagate probability starting from one of
the metastable states, and measure how much probability ends up in
each metastable state.
To adequately sample the conformational space explored by hDAT
in various conditions, we analyzed the population of microstates
throughout the simulations and restarted several rounds simulations
from those microstates that have been sampled least frequently.41
Conformational Analysis. DTM6e‑10e were calculated using centers
of mass (COMs) of Cα atoms of TM6e and TM10e residues (see
below) in hDAT, and the aligned 307−315 (TM6e) and 469−477
(TM10e) in dDAT. The volume of the EV and IV was measured by
computing the number of water molecules in the vestibules as
described in our previous studies.49,50 Dihedral angle and solvent
accessible surface area (SASA) were calculated with MDTraj (version
1.7.2)100 in combination with in-house Python scripts. All conforma-
tional analyses were calculated from 500 Bayesian Markov model
samples each with 100 frames sampled from those having >75%
probability of belonging to each MS.
We developed the pairwise interaction analyzer for DAT (PIA-
DAT), based on our previously developed PIA-GPCR.101 The
procedure and structural features measured by PIA-DAT are similar
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to PIA-GPCR described in101 and to the distance diﬀerence matrices
described in,102 and systematically quantify conformational diﬀerences
at both residue and subsegment levels. However, we took advantage of
MSM analysis results in this study in the pairwise comparison of two
compared conditions: the dominant MSs for each condition were
chosen for the comparison; similar to other analyses in this study, for
each MS, 500 Bayesian Markov model samples with 100 frames (of
those that have >75% probability to belong to their respective MSs)
were collected; the averages of structural features for each sample were
then averaged as the inputs for PIA-DAT.
For the analysis of coarse-grained interaction network of hDAT, we
deﬁned the following structural elements: NT (N terminus, residues
58−64), TM1i (the intracellular section (i) of TM1, residues 65−74),
TM1m (the middle section (m) of TM1, residues 75−82), TM1e (the
extracellular section (e) of TM1, residues 83−92), EL1 (the
extracellular loop 1, residues 93−95), TM2e (residues 96−101),
TM2m (residues 102−111), TM2i (residues 112−124), IL1 (residues
125−135), TM3i (residues 136−151), TM3m (residues 152−156),
TM3e (residues 157−172), EL2 (residues 173−237), TM4e (residues
238−246), TM4i (residues 247−255), IL2 (residues 256−261), TM5i
(residues 262−266), TM5m (residues 267−274), TM5e (residues
275−284), EL3 (residues 285−307), TM6e (residues 308−316),
TM6m (residues 317−328), TM6i (residues 329−335), IL3 (residues
336−342), TM7i (residues 343−352), TM7m (residues 353−359),
TM7e (residues 360−374), EL4a (residues 375−386), EL4b (residues
387−404), TM8e (residues 405−417), TM8m (residues 418−426),
TM8i (residues 427−436), IL4 (residues 437−441), TM9i (residues
445−454), TM9e (residues 455−465), EL5 (residues 466−469),
TM10e (residues 470−478), TM10m (residues 479−483), TM10i
(484−496), IL5 (residues 497−518), TM11i (residues 519−529),
TM11e (residues 530−540), EL6 (residues 541−557), TM12e
(residues 558−572), TM12i (residues 573−584), and CT (C
terminus, residues 585−600).
The ligand binding site residues were determined to be those that
are within 5 Å of ligand heavy atoms in >50% within the 500 Bayesian
Markov model samples with 100 frames (of those that have >75%
probability to belong to their respective MSs).
Quantum Mechanical and MM/GBSA Energy Calculations.
Quantum mechanical geometry optimizations and potential energies
of unbound JHW007 and CFT were obtained with DFT method using
the B3LYP/6-31G** basis set and water solvent model within the
Jaguar software103 of the Schrodinger suite (release 2016-1).
An MM/GBSA analysis for the JHW007 binding modes simulated
with the CHARMM36/GAAMP force ﬁeld was performed using the
protocol implemented in CHARMM (version 40b2)104 using the
GBSW implicit solvent model.105 The frames used for this analysis
were obtained from 500 Bayesian Markov model samples each with
100 frames sampled from those having >75% probability of belonging
to the most stable MS in each of the conditions (i.e., blue and green
MSs for equatorial and axial tNH JHW007, respectively). The MM/
GBSA analysis for the JHW007 binding modes simulated with the
OPLS3 force ﬁeld was performed using the Thermal MM/GBSA
module within the Schrodinger suite (release 2016−4), for the last 300
ns of each of the four OPLS3 trajectories with an interval of 3 ns.
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